MRNY ETF: YieldMax's Option Income Play on Moderna (MRNA)

Key Takeaways

• MRNY is an actively managed, non-diversified single-stock ETF that seeks current income through a synthetic covered call strategy on Moderna (MRNA), with secondary exposure to MRNA's share price subject to capped upside.
• The fund holds roughly 15 to 20 positions, led by U.S. Treasury bills used as options collateral, and distributes income weekly with a double-digit trailing distribution yield.
• MRNY carries a 1.00% net expense ratio and elevated portfolio turnover of roughly 340%, reflecting its monthly options rolling.
• Over the past 30 days, MRNY slipped about 2%, trading in a wide range as Moderna shares surged on oncology momentum before a sharp "sell-the-news" pullback.
• The capped-gains structure means MRNY participates only partially in MRNA rallies while retaining meaningful downside exposure to the underlying stock.

Understanding the MRNY ETF Structure

The YieldMax MRNA Option Income Strategy ETF (MRNY) is an actively managed exchange-traded fund listed on NYSE Arca and launched in October 2023. Its primary objective centers on current income, with a secondary goal of exposure to Moderna’s share price, though potential gains remain capped. The fund is non-diversified and concentrates risk around a single underlying security and related instruments.

MRNY implements a synthetic covered call strategy. It typically acquires Moderna call options and sells Moderna put options to replicate about 100% of the stock’s price movement, then writes short-dated calls struck modestly above the current share price to collect premium income. U.S. Treasury bills and a government money market fund serve as collateral. Because the written calls limit upside participation, the fund’s gains in rising markets stay constrained while it retains substantial downside exposure to Moderna.

The portfolio typically holds 15 to 20 positions, dominated by Treasury bills, the First American Government Obligations Fund, and long and short Moderna option contracts. The fund charges a 1.00% net expense ratio, distributes income weekly, and maintains portfolio turnover around 340% due to monthly options rolls. A 1-for-10 reverse split was completed in December 2025. I also checked this using Tickeron’s AI Screener to see how the fund compares to other option-income vehicles.

Moderna and the mRNA Landscape

MRNY’s performance ties almost entirely to Moderna and the broader messenger RNA therapeutics theme. After years of post-pandemic revenue decline from its COVID-19 vaccine franchise, Moderna has refocused investor attention on oncology, particularly its personalized cancer vaccine program developed with Merck (MRK).

In August 2026, the companies reported positive Phase 3 results for their individualized neoantigen therapy, intismeran autogene, combined with Merck’s Keytruda in high-risk melanoma. The announcement triggered an extraordinary single-day rally in Moderna shares and helped lift the stock more than 500% year-to-date. Detailed data presented later showed the combination reduced the risk of melanoma recurrence or death by 42% and the risk of distant metastasis or death by 38% versus Keytruda alone.

The sector backdrop includes competitive pressure from BioNTech and other mRNA developers, ongoing political and regulatory scrutiny of mRNA technology, and sensitivity to interest rates that affect valuations of unprofitable growth-stage biotechnology companies. For MRNY, elevated implied volatility in Moderna options has historically supported higher option premiums, a key input to the fund’s income generation.

Recent Performance and Market Moves

Over the most recent 30 days, MRNY declined roughly 2%, a modest net move that masked considerable intraday and weekly volatility. The fund traded from the low $30s into the mid-$40s as Moderna’s rally extended, before reversing sharply when detailed melanoma trial data triggered a “sell-the-news” selloff that knocked Moderna down more than 17% in a single session; MRNY fell roughly 12% in the same session as its synthetic exposure transmitted the underlying stock’s decline.

This pattern illustrates the structural trade-off embedded in MRNY. Over 2026, Moderna’s share price rose several hundred percent, yet MRNY’s advance was far more limited because its written call options cap each period’s upside. Meanwhile, the fund’s double-digit trailing distribution yield reflects both the high option premiums available on a volatile stock and the fund’s return of capital characteristics. Investors receive substantial income but should not expect MRNY to mirror Moderna’s price appreciation. From what I see, this capped participation is a point worth monitoring closely when comparing total returns.

2026 Outlook and Key Factors to Monitor

Several structural factors are likely to shape MRNY over the coming months. First, Moderna’s regulatory and clinical progress will dominate: the company expects its melanoma vaccine to launch as early as 2027, with additional readouts in renal cell and bladder cancer expected to clarify whether the personalized approach extends beyond a single tumor type. Second, manufacturing economics matter, given that each individualized dose can take weeks to produce.

Third, MRNY’s income profile depends on continued options volatility; a sharp drop in Moderna’s implied volatility could compress the premiums the fund collects. Fourth, the capped-gains design means the fund will structurally underperform Moderna in any sustained rally, a consideration for investors weighing income against total return. Finally, expense ratio, portfolio turnover, and the fund’s non-diversified, single-stock concentration remain persistent risk factors. Investors should monitor oncology data, regulatory decisions, interest-rate expectations, and biotech sector capital flows rather than relying on short-term price swings. I’m watching this closely as new trial readouts approach.

Exploring Tickeron’s AI Tools for Deeper Analysis

In my own research process, I occasionally turn to Tickeron’s AI Screener to quickly compare single-stock income ETFs like MRNY against peers using volatility metrics, technical patterns, and industry filters. It surfaces comparable vehicles and helps assess momentum shifts without manual effort. The platform’s ability to incorporate AI-generated signals has become a regular part of how I evaluate these strategies alongside traditional data sources.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Contributor

Allana|Expert

Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.

Industry description